Overview

A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

Status:
Completed
Trial end date:
2018-04-29
Target enrollment:
Participant gender:
Summary
A Single-Center study to demonstrate the non-inferiority of EM-100 to Zaditor® in the treatment of ocular itching.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch & Lomb Incorporated
EyeMax, LLC
Collaborators:
Eton Pharmaceuticals, Inc.
ORA, Inc.
Treatments:
Ketotifen
Ophthalmic Solutions